These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 3134744)
1. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Vandekerckhove Y; Baele G; De Puydt H; Weyne A; Clement D Thromb Res; 1988 May; 50(3):449-53. PubMed ID: 3134744 [No Abstract] [Full Text] [Related]
2. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Rabijewski M; Zgliczyński W Endokrynol Pol; 2007; 58(3):213-9. PubMed ID: 17940987 [TBL] [Abstract][Full Text] [Related]
3. [Changes in plasma tissue-type plasminogen activator and its inhibitor in coronary heart disease and diabetic patients and their clinical significance]. Zhou L Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Oct; 18(5):282-4. PubMed ID: 2128270 [No Abstract] [Full Text] [Related]
4. [Effects of guan-mai-shu on tissue-type plasminogen activator and plasminogen activator inhibitor in the plasma of patients with coronary heart disease]. Xiong XZ; Mo SS Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Dec; 13(12):727-9, 708-9. PubMed ID: 8136646 [TBL] [Abstract][Full Text] [Related]
5. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Olofsson BO; Dahlén G; Nilsson TK Eur Heart J; 1989 Jan; 10(1):77-82. PubMed ID: 2495219 [TBL] [Abstract][Full Text] [Related]
6. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149 [TBL] [Abstract][Full Text] [Related]
7. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Terres W; Lund GK; Hübner A; Ehlert A; Reuter H; Hamm CW Am Heart J; 1995 Oct; 130(4):711-6. PubMed ID: 7572577 [TBL] [Abstract][Full Text] [Related]
8. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease. Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039 [TBL] [Abstract][Full Text] [Related]
9. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044 [TBL] [Abstract][Full Text] [Related]
10. Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study. May M; Lawlor DA; Patel R; Rumley A; Lowe G; Ebrahim S Eur J Cardiovasc Prev Rehabil; 2007 Oct; 14(5):638-45. PubMed ID: 17925622 [TBL] [Abstract][Full Text] [Related]
12. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjö, Sweden. Hellsten G; Boman K; Bjerle P; Blom P; Nilsson TK Eur Heart J; 1992 Jan; 13(1):57-60. PubMed ID: 1577032 [TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Jansson JH; Nilsson TK; Olofsson BO Eur Heart J; 1991 Feb; 12(2):157-61. PubMed ID: 1904350 [TBL] [Abstract][Full Text] [Related]
14. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease. Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597 [TBL] [Abstract][Full Text] [Related]
15. [Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]. Zateĭshchikov DA; Averkov OV; Gratsianskiĭ NA; Dobrovol'skiĭ AB; Storozhilova AN Kardiologiia; 1992 Feb; 32(2):9-12. PubMed ID: 1527946 [TBL] [Abstract][Full Text] [Related]
16. Impaired fibrinolysis in coronary artery disease. Francis RB; Kawanishi D; Baruch T; Mahrer P; Rahimtoola S; Feinstein DI Am Heart J; 1988 Apr; 115(4):776-80. PubMed ID: 3128096 [TBL] [Abstract][Full Text] [Related]
17. Plasma Lp(a) and t-PA-PAI-1 complex levels in coronary heart disease. Süer S; Ulutin T; Sönmez H; Kökoğlu E; Uçişik N; Bayram C; Sultuybek G Thromb Res; 1996 Jul; 83(1):77-85. PubMed ID: 8837306 [TBL] [Abstract][Full Text] [Related]
18. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease. Caputo M; Mantini G; Floriani I; Ciceri M; Noseda A; Bonomo L Eur Heart J; 1996 Sep; 17(9):1329-36. PubMed ID: 8880017 [TBL] [Abstract][Full Text] [Related]